[Hypofractionated whole breast irradiation (WBRT): Results and indications].
Breast irradiation after breast-conserving surgery is essential for maximizing local control and overall survival. The increase of breast cancer (BC) incidence, constraints of classical five weeks (w) radiation regimens and scarcity of radiotherapy units have led to test short hypofractionated WBRT schemes. One pilot study and three prospective randomized trials have tested various hypofractionated regimens of WBRT. About 7000 patients were included and follow-up ranged from 5 to 12 years. The conclusion of these trials is similar, showing local control and toxicity equivalent to these of the standard regimens. Three schemes are now clearly validated: 42.5Gy/16fr/3w, 40Gy/15fr/3w, or 42Gy/13fr/5w. However, the majority of included patients had favorable prognostic factors, were treated to the breast only and the boost dose, when indicated, was delivered with a standard fractionation. Therefore, we recommend the regimens preferentially in patients treated to the breast only, and without nodal involvement. These studies did not evaluate the addition of a boost dose with a hypofractionated scheme. If a boost is to be given, a standard fractionation should be used. Particular care should be taken to avoid heterogeneities leading to high fraction doses to organs at risk (lung and heart).
Institut du cancer Courlancy, 38, rue de Courlancy, 51100 Reims, France. Electronic address: bcutuli@iccreims.fr.
B
B
Cutuli
D001943:Breast Neoplasms / Q000532:radiotherapy* / Q000601:surgery; D002986:Clinical Trials as Topic; D005260:Female; D006321:Heart / Q000528:radiation effects; D006801:Humans; D008198:Lymph Nodes / Q000528:radiation effects; D015412:Mastectomy, Segmental; D058958:Organs at Risk; D000069473:Radiation Dose Hypofractionation; D018714:Radiotherapy, Adjuvant
Breast cancer; Cancer du sein; Contrôle local; Hypofractionation; Hypofractionnement; Local control; Radiotherapy; Radiothérapie; Tolerance; Tolérance